Viropro Stock Performance
Viropro holds a performance score of 9 on a scale of zero to a hundred. The entity has a beta of -0.47, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Viropro are expected to decrease at a much lower rate. During the bear market, Viropro is likely to outperform the market. Use Viropro market risk adjusted performance and treynor ratio , to analyze future returns on Viropro.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Viropro are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Viropro displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Viropro Relative Risk vs. Return Landscape
If you would invest 0.00 in Viropro on September 27, 2025 and sell it today you would earn a total of 0.00 from holding Viropro or generate 9.223372036854776E16% return on investment over 90 days. Viropro is currently generating 15.625% in daily expected returns and assumes 125.0% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Viropro, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viropro Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viropro's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viropro, and traders can use it to determine the average amount a Viropro's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.125
| Best Portfolio | Best Equity | VPRO | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Viropro is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viropro by adding it to a well-diversified portfolio.
Viropro Fundamentals Growth
Viropro Stock prices reflect investors' perceptions of the future prospects and financial health of Viropro, and Viropro fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viropro Stock performance.
| Operating Margin | (2.09) % | ||||
| Current Valuation | 11.91 M | ||||
| Shares Outstanding | 916.09 M | ||||
| Price To Earning | 0.10 X | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 18.15 X | ||||
| Revenue | 571.1 K | ||||
| Cash And Equivalents | 119.25 K | ||||
| Total Debt | 175.56 K | ||||
| Debt To Equity | 0.57 % | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (675.62 K) | ||||
| Total Asset | 2.11 M | ||||
| Retained Earnings | (17 M) | ||||
| Current Asset | 291 K | ||||
| Current Liabilities | 3.16 M | ||||
About Viropro Performance
By examining Viropro's fundamental ratios, stakeholders can obtain critical insights into Viropro's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Viropro is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. VIROPRO INC operates under Biotechnology classification in the United States and is traded on PNK Exchange.Things to note about Viropro performance evaluation
Checking the ongoing alerts about Viropro for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viropro help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viropro is way too risky over 90 days horizon | |
| Viropro has some characteristics of a very speculative penny stock | |
| Viropro appears to be risky and price may revert if volatility continues | |
| Viropro has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 571.1 K. Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viropro currently holds about 119.25 K in cash with (675.62 K) of positive cash flow from operations. | |
| Viropro has a very weak financial position based on the latest SEC disclosures |
- Analyzing Viropro's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viropro's stock is overvalued or undervalued compared to its peers.
- Examining Viropro's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viropro's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viropro's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viropro's stock. These opinions can provide insight into Viropro's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viropro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viropro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Viropro is measured differently than its book value, which is the value of Viropro that is recorded on the company's balance sheet. Investors also form their own opinion of Viropro's value that differs from its market value or its book value, called intrinsic value, which is Viropro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viropro's market value can be influenced by many factors that don't directly affect Viropro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viropro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.